Background illustration for clinical trials search

Gene Therapy Clinical Trials

Find clinical trials for gene therapy. Search for gene therapy clinical trials in different cities and states across the United States.

Filter

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

for
Large B-cell Lymphoma
Location: St Louis MO
Sponsor: Washington University School of Medicine

Sex: All

Age: 18+

Code: NCT07052305

Phase 1, Recruiting

Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)

for
Relapsed / Refractory Osteosarcoma
Location: Boston MA, Los Angeles CA
Sponsor: Lantheus Medical Imaging

Sex: All

Age: 12+

Code: NCT07357519

Phase 1, Phase 2, Recruiting

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

for
B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Location: Charleston SC
Sponsor: Medical University of South Carolina

Sex: All

Age: 18+

Code: NCT05702853

Phase 1, Phase 2, Recruiting

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

for
Recurrent B-Cell Non-Hodgkin Lymphoma,
Location: Rochester MN
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT04892277

Phase 1, Recruiting

Dextenza in the Post-op Management of Vitreoretinal Surgeries

for
Vitreoretinal Surgery, Ocular Inflammation, Post-operative Pain,
Location: Cleveland OH
Sponsor: The Cleveland Clinic

Sex: All

Age: 18+

Code: NCT04371445

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Postoperative Analgesia Intervention With Non-opioid Alternatives (PAIN-Alt) Trial - Breast Surgery

for
Post Operative Pain, Opioid Analgesic Adverse Reaction, Surgery,
Location: Montreal
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

Sex: All

Age: 18+

Code: NCT06507345

Recruiting

Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

for
Recurrent Diffuse Large B-Cell Lymphoma,
Location: Duarte CA
Sponsor: City of Hope Medical Center

Sex: All

Age: 18+

Code: NCT05800405

Early Phase 1, Recruiting

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

for
Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation
Location: Tampa FL
Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Sex: All

Age: 18+

Code: NCT04741997

Early Phase 1, Recruiting

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

for
Metastatic Clear Cell Renal Cell Carcinoma,
Location: Saint Johnsbury VT, Lebanon NH, Lake Success NY,
Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT04510597

Phase 3, Recruiting

Hyperfractionated Dual Equivalent Fractionated Radiation Therapy

for
Diffuse Large B-Cell Lymphoma
Location: New Haven CT
Sponsor: Yale University

Sex: All

Age: 18+

Code: NCT06898905

Recruiting

CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

for
AML/MDS, B-ALL, T-ALL, BPDCN
Location: Memphis TN
Sponsor: St. Jude Children's Research Hospital

Sex: All

Age: 0 - 21

Code: NCT04318678

Phase 1, Recruiting

A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.

for
Severe Hemophilia A
Location: Greenville NC, Los Angeles CA
Sponsor: Pfizer

Sex: Male

Age: 12 - 70+

Code: NCT06703606

Phase 1, Recruiting

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

for
B Cell Lymphoma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06213311

Phase 2, Recruiting

Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease

for
Post-Treatment Lyme Disease
Location: East Syracuse NY
Sponsor: State University of New York - Upstate Medical University

Sex: All

Age: 18 - 70+

Code: NCT06611111

Early Phase 1, Recruiting

Flexible Insulin Therapy Untethered Insulin Regimen in Avidly Exercising Patients With Type 1 Diabetes: FIT Untethered

for
Type 1 Diabetes Mellitus
Location: Toronto
Sponsor: LMC Diabetes & Endocrinology Ltd.

Sex: All

Age: 18 - 55

Code: NCT03838783

Recruiting

Mitigating the Pro-inflammatory Phenotype of Obesity

for
Blood Pressure, Diabetes, Obesity, Insulin Resistance,
Location: Kansas City KS
Sponsor: University of Kansas Medical Center

Sex: All

Age: 18 - 70+

Code: NCT04934228

Phase 1, Recruiting

OurSleepKit To Support CPAP Adherence

for
Obstructive Sleep Apnea, CPAP Treatment, Treatment Adherence
Location: Pittsburgh PA
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Sex: All

Age: 18+

Code: NCT06621511

Recruiting

Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma

for
Oropharyngeal Squamous Cell Carcinoma
Location: St Louis MO
Sponsor: Washington University School of Medicine

Sex: All

Age: 18+

Code: NCT04852328

Phase 2, Recruiting

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

for
B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins,
Location: Cleveland OH, Dallas TX, Salt Lake City UT, Portland OR,
Sponsor: Estrella Immunopharma, Inc.

Sex: All

Age: 18+

Code: NCT06343311

Phase 1, Phase 2, Recruiting

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

for
Advanced Basal Cell Carcinoma
Location: Tampa FL
Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Sex: All

Age: 18+

Code: NCT05651828

Early Phase 1, Recruiting

What is gene therapy, and how does it work?

Many diseases come from a single gene that is missing, broken, or overactive. Gene therapy aims to correct that instead of treating the symptoms. There are three main approaches. Gene addition delivers a working copy of the gene, usually inside a harmless modified virus called a vector, most often an adeno associated virus (AAV). Gene silencing turns down a harmful gene. Gene editing, using tools like CRISPR, cuts and repairs the DNA itself. The therapy can be given directly into the body, as an infusion or an injection into the eye or spinal fluid, or done outside it: stem cells are collected, modified in a lab, and returned, which is how sickle cell gene therapies work.

Approved examples show the range. Luxturna (2017) restores some vision in a rare inherited blindness. Zolgensma (2019) treats spinal muscular atrophy in infants with a single infusion. Hemgenix (2022) lets many people with hemophilia B stop regular factor infusions. Casgevy (December 2023) was the first CRISPR based medicine, for sickle cell disease and beta thalassemia. Most trials today are in rare genetic diseases, inherited eye and blood disorders, and neurological conditions, with growing work in more common diseases like heart failure and Parkinson's. Our article on the future of gene therapy in clinical trials goes deeper.

Types of gene therapy clinical trials

How much does gene therapy cost?

Who can participate in gene therapy trials?

Do gene therapy trial participants get paid?

How to enroll in a gene therapy clinical trial